{"id":"vancomycin-plus-gentamicin-plus-rifampin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Red man syndrome (vancomycin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Gentamicin is an aminoglycoside that binds to the 30S ribosomal subunit, inhibiting protein synthesis. Rifampin inhibits bacterial RNA polymerase, blocking transcription. This triple combination provides synergistic bactericidal activity against difficult-to-treat infections, particularly gram-positive organisms and some gram-negative bacteria.","oneSentence":"This triple-antibiotic combination kills bacteria through three complementary mechanisms: vancomycin and gentamicin inhibit protein synthesis and cell wall integrity, while rifampin inhibits bacterial RNA polymerase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:25.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prosthetic valve endocarditis"},{"name":"Complex or resistant bacterial infections requiring synergistic therapy"}]},"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00304811","phase":"PHASE4","title":"Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection","status":"COMPLETED","sponsor":"Michael E. DeBakey VA Medical Center","startDate":"2006-01","conditions":"Staphylococcus Aureus","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin plus Gentamicin plus Rifampin","genericName":"Vancomycin plus Gentamicin plus Rifampin","companyName":"Michael E. DeBakey VA Medical Center","companyId":"michael-e-debakey-va-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin has been studied in combination with Gentamicin and Rifampin for the treatment of Staphylococcus Aureus infections, specifically osteomyelitis. The combination of Vancomycin and Gentamicin has been compared to Vancomycin alone in clinical trials for the treatment of MRSA infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}